MS4A6A (Membrane-Spanning 4-Domains A6A) is a member of the membrane-spanning 4-domains A (MS4A) gene family. This gene encodes a tetraspanin-like membrane protein that is primarily expressed in immune cells, particularly in cells of the myeloid lineage including [microglia](/cell-types/microglia-neuroinflammation) in the brain. MS4A6A has emerged as a significant genetic risk factor for Alzheimer's disease (AD) through genome-wide association studies (GWAS).
MS4A6A (Membrane-Spanning 4-Domains A6A) is a member of the membrane-spanning 4-domains A (MS4A) gene family. This gene encodes a tetraspanin-like membrane protein that is primarily expressed in immune cells, particularly in cells of the myeloid lineage including [microglia](/cell-types/microglia-neuroinflammation) in the brain. MS4A6A has emerged as a significant genetic risk factor for Alzheimer's disease (AD) through genome-wide association studies (GWAS).
Gene and Protein Structure
The MS4A6A gene is located on chromosome 11q12.2, within a cluster of MS4A genes (MS4A1-MS4A6). The gene encodes a 246-amino acid protein with: [@hollingworth2011]
Four transmembrane domains
Intracellular N- and C-termini
Two extracellular loops
A conserved CD20-like structure
The MS4A family includes at least 12 genes with similar structure, many of which have roles in immune cell signaling and function. [@vasquez2013]
Normal Function in the Nervous System
In the nervous system, MS4A6A is primarily expressed in: [@proitsi2015]
Microglia: The brain's resident immune cells
MS4A6A is highly expressed in microglia, especially in white matter
Regulates microglial activation and inflammatory responses
Modulates phagocytic activity
Myeloid Cells: Including monocytes and macrophages
Involved in calcium signaling
Regulates cell surface receptor expression
Limited Neuronal Expression: Low expression in certain neuronal populations
Role in Neurodegenerative Diseases
Alzheimer's Disease (AD)
MS4A6A is one of the most significant AD risk genes identified by GWAS: [@jiang2022]
Genetic association: Multiple GWAS have identified SNPs in the MS4A6A locus as associated with reduced AD risk
Effect size: MS4A6A variants modify AD risk by approximately 10-15%
Mechanism: The risk allele is associated with:
Increased microglial activation
Altered lipid metabolism
Changes in amyloid processing
Dysregulated immune response
Multiple Sclerosis (MS)
Given its immune cell expression, MS4A6A variants may influence multiple sclerosis susceptibility:
Altered microglial function
Modified inflammatory responses
Other Neurological Conditions
Emerging evidence suggests MS4A6A may play roles in:
Parkinson's disease: Microglial involvement
ALS: Neuroinflammation
Therapeutic Implications
MS4A6A represents a promising therapeutic target:
Microglial Modulation: Targeting MS4A6A to reduce harmful neuroinflammation
AD Prevention: Individuals with protective variants may inform therapeutic strategies
Biomarker Potential: MS4A6A expression or variants as AD biomarkers
Immunomodulatory Therapies: Understanding MS4A6A function may guide immune-based AD treatments
Expression Patterns
Brain: High expression in microglia, particularly in white matter regions
Immune tissues: Spleen, lymph nodes, bone marrow
Blood: Monocytes, B-cells (lower expression)
Expression increases with age in brain tissue.
Interactions and Pathways
MS4A6A interacts with:
MS4A family proteins: Forms complexes with other MS4A proteins
MS4A6A is a microglial-expressed protein that has emerged as a significant genetic risk factor for Alzheimer's disease. Its role in modulating microglial function and immune responses makes it a compelling therapeutic target for AD and potentially other neurodegenerative diseases characterized by neuroinflammation.